Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
Category: #health  | By Mateen Dalal  | Date: 2019-09-16 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
  • Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB.
  • In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethasone and melflfufen in RRMM patients suffering from EMD.

Oncopeptides AB, a pharmaceutical company established in 2000 aimed at developing drugs to treat cancer, reportedly announced interim safety and efficacy data update from the ongoing Phase 2 HORIZON trial during 17th International Myeloma Workshop (IMW) being conducted at Boston, Massachusetts, USA.  

The outcomes presented during IMW 2019 by Prof. Paul G Richardson during the plenary session “Late Breaking Abstracts” with title name: Activity of Melflufen in RRMM Patients with EMD(Extramedullary Disease) in Phase 2 Study (OP-106 HORIZON) – promising outcomes in a high-risk population, are further based on a data cur from the company’s HORIZON trial conducted in July of 2019 when 136 participants were treated in comparison to earlier reported data which included 121 patients.

HORIZON represents the biggest clinical cohort based on literature till date of patients having myeloma that are diagnosed with extra medullary disease (EMD).

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) is a population that is highly difficult to treat. In very recent single-agent trial (without or with steroids) comprising RRMM patients having EMD have demonstrated overall response rates (ORR) falling between 0 – 17%.

Only daratumumab has been able to show any relavant clinical activity having an overall response rate of 17% in patients with daratumumab naïve myeloma with EMD.

In the HORIZON trial, an ORR (overall response rate) of 23% was achieved when treated with dexamethasone and melflfufen in RRMM patients suffering from EMD. Mainly, penta refractory patients were found under this category (who have undergone five prior treatments at least and were resistant to a minimum of one proteasome inhibitor, one anti-CD38 and IMiD treatment).

Source credit: https://www.oncopeptides.se/en/new-interim-data-in-rrmm-patients-with-extramedullary-disease-from-the-pivotal-phase-2-horizon-study-presented-at-international-myeloma-workshop/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...